MovDisordV3, PascalFrancis, Curation, bibRecord, 002088

The Effect of Peripheral Enzyme Inhibitors on Levodopa Concentrations in Blood and CSF

Identifieur interne : 002088 ( PascalFrancis/Curation ); précédent : 002087; suivant : 002089

The Effect of Peripheral Enzyme Inhibitors on Levodopa Concentrations in Blood and CSF

Auteurs : Maria Nord [Suède] ; Peter Zsigmond [Suède] ; Anita Kullman [Suède] ; Kerstin Arstrand [Suède] ; Nil Dizdar [Suède]

Source :

Movement disorders [ 0885-3185 ] ; 2010.

RBID : Pascal:10-0161576

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Inhibiteur enzyme, Lévodopa, Liquide céphalorachidien.

English descriptors

KwdEn :
- Cerebrospinal fluid, Enzyme inhibitor, Levodopa, Nervous system diseases, Parkinson disease.

Abstract

Levodopa combined with a dopa-decarboxylase inhibitor, such as carbidopa, shifts the metabolism to the COMT pathway. Adding the peripheral acting COMT inhibitor entacapone provides improvement for patients with PD suffering from motor fluctuations. We studied the effects of the enzyme inhibitors entacapone and carbidopa on the levodopa concentrations in CSF and in blood. Five PD patients with wearing-off underwent lumbar drainage and intravenous microdialysis. Samples were taken 12 h daily for 3 days. Day 1; intravenous levodopa was given, day 2; additional oral entacapone 200 mg tid, day 3; additional oral entacapone 200 mg tid and carbidopa 25 mg bid. Levodopa in CSF and in dialysates was analysed. The AUC for levodopa increased both in blood and CSF when additional entacapone was given alone and in combination with carbidopa. The C_max of levodopa in both CSF and blood increased significantly. Additional entacapone to levodopa therapy gives an increase of C_max in CSF and in blood. The increase is more evident when entacapone is combined with carbidopa.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 25`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 The Effect of Peripheral Enzyme Inhibitors on Levodopa Concentrations in Blood and CSF`
A11	`01`	`1`		`@1 NORD (Maria)`
A11	`02`	`1`		`@1 ZSIGMOND (Peter)`
A11	`03`	`1`		`@1 KULLMAN (Anita)`
A11	`04`	`1`		`@1 ARSTRAND (Kerstin)`
A11	`05`	`1`		`@1 DIZDAR (Nil)`
A14	`01`			`@1 Department of Neurology, University Hospital @2 Linköping @3 SWE @Z 1 aut. @Z 5 aut.`
A14	`02`			`@1 Department of Neurosurgery, University Hospital @2 Linköping @3 SWE @Z 2 aut.`
A14	`03`			`@1 Department of Clinical Chemistry, University Hospital @2 Linköping @3 SWE @Z 3 aut. @Z 4 aut. @Z 5 aut.`
A20				`@1 363-367`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000181820230150`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 30 ref.`
A47	`01`	`1`		`@0 10-0161576`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Levodopa combined with a dopa-decarboxylase inhibitor, such as carbidopa, shifts the metabolism to the COMT pathway. Adding the peripheral acting COMT inhibitor entacapone provides improvement for patients with PD suffering from motor fluctuations. We studied the effects of the enzyme inhibitors entacapone and carbidopa on the levodopa concentrations in CSF and in blood. Five PD patients with wearing-off underwent lumbar drainage and intravenous microdialysis. Samples were taken 12 h daily for 3 days. Day 1; intravenous levodopa was given, day 2; additional oral entacapone 200 mg tid, day 3; additional oral entacapone 200 mg tid and carbidopa 25 mg bid. Levodopa in CSF and in dialysates was analysed. The AUC for levodopa increased both in blood and CSF when additional entacapone was given alone and in combination with carbidopa. The C_max of levodopa in both CSF and blood increased significantly. Additional entacapone to levodopa therapy gives an increase of C_max in CSF and in blood. The increase is more evident when entacapone is combined with carbidopa.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B02U01`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Inhibiteur enzyme @5 09`
C03	`03`	`X`	`ENG`	`@0 Enzyme inhibitor @5 09`
C03	`03`	`X`	`SPA`	`@0 Inhibidor enzima @5 09`
C03	`04`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 10`
C03	`04`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 10`
C03	`04`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 10`
C03	`05`	`X`	`FRE`	`@0 Liquide céphalorachidien @5 11`
C03	`05`	`X`	`ENG`	`@0 Cerebrospinal fluid @5 11`
C03	`05`	`X`	`SPA`	`@0 Líquido cefalorraquídeo @5 11`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 102`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000C31

Links to Exploration step

Pascal:10-0161576

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The Effect of Peripheral Enzyme Inhibitors on Levodopa Concentrations in Blood and CSF</title>
<author><name sortKey="Nord, Maria" sort="Nord, Maria" uniqKey="Nord M" first="Maria" last="Nord">Maria Nord</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University Hospital</s1>
<s2>Linköping</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
<author><name sortKey="Zsigmond, Peter" sort="Zsigmond, Peter" uniqKey="Zsigmond P" first="Peter" last="Zsigmond">Peter Zsigmond</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurosurgery, University Hospital</s1>
<s2>Linköping</s2>
<s3>SWE</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
<author><name sortKey="Kullman, Anita" sort="Kullman, Anita" uniqKey="Kullman A" first="Anita" last="Kullman">Anita Kullman</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Clinical Chemistry, University Hospital</s1>
<s2>Linköping</s2>
<s3>SWE</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
<author><name sortKey="Arstrand, Kerstin" sort="Arstrand, Kerstin" uniqKey="Arstrand K" first="Kerstin" last="Arstrand">Kerstin Arstrand</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Clinical Chemistry, University Hospital</s1>
<s2>Linköping</s2>
<s3>SWE</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
<author><name sortKey="Dizdar, Nil" sort="Dizdar, Nil" uniqKey="Dizdar N" first="Nil" last="Dizdar">Nil Dizdar</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University Hospital</s1>
<s2>Linköping</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Clinical Chemistry, University Hospital</s1>
<s2>Linköping</s2>
<s3>SWE</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0161576</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0161576 INIST</idno>
<idno type="RBID">Pascal:10-0161576</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C31</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002088</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The Effect of Peripheral Enzyme Inhibitors on Levodopa Concentrations in Blood and CSF</title>
<author><name sortKey="Nord, Maria" sort="Nord, Maria" uniqKey="Nord M" first="Maria" last="Nord">Maria Nord</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University Hospital</s1>
<s2>Linköping</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
<author><name sortKey="Zsigmond, Peter" sort="Zsigmond, Peter" uniqKey="Zsigmond P" first="Peter" last="Zsigmond">Peter Zsigmond</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurosurgery, University Hospital</s1>
<s2>Linköping</s2>
<s3>SWE</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
<author><name sortKey="Kullman, Anita" sort="Kullman, Anita" uniqKey="Kullman A" first="Anita" last="Kullman">Anita Kullman</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Clinical Chemistry, University Hospital</s1>
<s2>Linköping</s2>
<s3>SWE</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
<author><name sortKey="Arstrand, Kerstin" sort="Arstrand, Kerstin" uniqKey="Arstrand K" first="Kerstin" last="Arstrand">Kerstin Arstrand</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Clinical Chemistry, University Hospital</s1>
<s2>Linköping</s2>
<s3>SWE</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
<author><name sortKey="Dizdar, Nil" sort="Dizdar, Nil" uniqKey="Dizdar N" first="Nil" last="Dizdar">Nil Dizdar</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University Hospital</s1>
<s2>Linköping</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Clinical Chemistry, University Hospital</s1>
<s2>Linköping</s2>
<s3>SWE</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cerebrospinal fluid</term>
<term>Enzyme inhibitor</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Inhibiteur enzyme</term>
<term>Lévodopa</term>
<term>Liquide céphalorachidien</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Levodopa combined with a dopa-decarboxylase inhibitor, such as carbidopa, shifts the metabolism to the COMT pathway. Adding the peripheral acting COMT inhibitor entacapone provides improvement for patients with PD suffering from motor fluctuations. We studied the effects of the enzyme inhibitors entacapone and carbidopa on the levodopa concentrations in CSF and in blood. Five PD patients with wearing-off underwent lumbar drainage and intravenous microdialysis. Samples were taken 12 h daily for 3 days. Day 1; intravenous levodopa was given, day 2; additional oral entacapone 200 mg tid, day 3; additional oral entacapone 200 mg tid and carbidopa 25 mg bid. Levodopa in CSF and in dialysates was analysed. The AUC for levodopa increased both in blood and CSF when additional entacapone was given alone and in combination with carbidopa. The C<sub>max</sub>
 of levodopa in both CSF and blood increased significantly. Additional entacapone to levodopa therapy gives an increase of C<sub>max</sub>
 in CSF and in blood. The increase is more evident when entacapone is combined with carbidopa.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>The Effect of Peripheral Enzyme Inhibitors on Levodopa Concentrations in Blood and CSF</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>NORD (Maria)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ZSIGMOND (Peter)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KULLMAN (Anita)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>ARSTRAND (Kerstin)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>DIZDAR (Nil)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, University Hospital</s1>
<s2>Linköping</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurosurgery, University Hospital</s1>
<s2>Linköping</s2>
<s3>SWE</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Clinical Chemistry, University Hospital</s1>
<s2>Linköping</s2>
<s3>SWE</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>363-367</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000181820230150</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>30 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0161576</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Levodopa combined with a dopa-decarboxylase inhibitor, such as carbidopa, shifts the metabolism to the COMT pathway. Adding the peripheral acting COMT inhibitor entacapone provides improvement for patients with PD suffering from motor fluctuations. We studied the effects of the enzyme inhibitors entacapone and carbidopa on the levodopa concentrations in CSF and in blood. Five PD patients with wearing-off underwent lumbar drainage and intravenous microdialysis. Samples were taken 12 h daily for 3 days. Day 1; intravenous levodopa was given, day 2; additional oral entacapone 200 mg tid, day 3; additional oral entacapone 200 mg tid and carbidopa 25 mg bid. Levodopa in CSF and in dialysates was analysed. The AUC for levodopa increased both in blood and CSF when additional entacapone was given alone and in combination with carbidopa. The C<sub>max</sub>
 of levodopa in both CSF and blood increased significantly. Additional entacapone to levodopa therapy gives an increase of C<sub>max</sub>
 in CSF and in blood. The increase is more evident when entacapone is combined with carbidopa.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Enzyme inhibitor</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Inhibidor enzima</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Liquide céphalorachidien</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Cerebrospinal fluid</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Líquido cefalorraquídeo</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>102</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002088 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 002088 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:10-0161576
   |texte=   The Effect of Peripheral Enzyme Inhibitors on Levodopa Concentrations in Blood and CSF
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

The Effect of Peripheral Enzyme Inhibitors on Levodopa Concentrations in Blood and CSF

The Effect of Peripheral Enzyme Inhibitors on Levodopa Concentrations in Blood and CSF

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri